[Eosinophilia-myalgia syndrome. Clinical aspects and follow-up of 10 patients].
A retrospective study (1985-1989) of patients suffering from diffuse fasciitis with eosinophilia revealed that five of eight patients had taken L-tryptophan-containing drugs before the onset of the disease. In addition, since this drug-disease association was first described five patients have been diagnosed during the year 1990. All ten patients developed peripheral eosinophilia, myalgia and deep skin involvement indistinguishable from eosinophilic fasciitis. Corticosteroids were able to reduce the pain and inflammatory parameters, but did not prophylactically improve the long-standing sclerodermalike skin thickening. In 2/5 patients with symptoms longer than 1 year, low-dose corticosteroid maintenance therapy has been continuously required to control joint and muscle pain.
Mensing
H
H
Universitäts-Hautklinik Hamburg.
Schallreuter
K U
KU
Senff
H
H
Steinkraus
V
V
D000328:Adult; D000368:Aged; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D016603:Eosinophilia-Myalgia Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D012867:Skin / Q000473:pathology; D014364:Tryptophan / Q000008:administration & dosage / Q000009:adverse effects*
D014364:Tryptophan
Das Eosinophilie-Myalgie-Syndrom. Klinik und Verlauf bei 10 Patienten.